Received May 8, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPA | HEP A (HAVRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | DN273 | — |
29 years old Patient and she received the pediatric dose; 29 years old Patient and she received the pediatric dose; This non-serious case was reported by a nurse via call center representative and described the occurrence of adult use of a child product in a 29-year-old female patient who received HAV (Havrix pediatric) (batch number DN273, expiry date 28-AUG-2026) for prophylaxis. On 16-APR-2025, the patient received the 1st dose of Havrix pediatric. On 16-APR-2025, an unknown time after receiving Havrix pediatric, the patient experienced adult use of a child product (Verbatim: 29 years old Patient and she received the pediatric dose) and underdose (Verbatim: 29 years old Patient and she received the pediatric dose). The outcome of the adult use of a child product and underdose were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 29-APR-2025 Nurse reported they had a patient of 29 years old and she received the pediatric dose of Havrix. So wanted to know what the next step is to restart the series with the adult dose. Adult patient received pediatric dose of Havrix, which led to adult use of child product and underdose.